Findings seen among adult psychiatric inpatients taking an antipsychotic<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Sept. 20, 2024 (HealthDay News) \u00e2\u0080\u0093 There is no correlation between high-density lipoprotein cholesterol (HDL-C) levels and a patient’s risk for developing movement disorders while taking an antipsychotic, according to a study published in the April-June issue of\u00a0Innovations in Clinical Neuroscience<\/em>.<\/p>\n Carolyn O\u00e2\u0080\u0099Donnell, Pharm.D., from the Edward Hines Jr. Veterans Administration Hospital in Hines, Illinois, and colleagues investigated associations between patients taking antipsychotics with low HDL-C and the risk for developing a movement disorder. The analysis included 89 adult patients at an inpatient state psychiatric facility.<\/p>\n The researchers report that only eight patients had an Abnormal Involuntary Movement Scale score greater than 0 and HDL-C levels ranged from 17 mg\/dL to 83 mg\/dL. There was no statistically significant association seen when comparing a patient’s movement disorder, Abnormal Involuntary Movement Scale scores, and HDL-C levels.<\/p>\n “It is our hope that our research will support prioritized prescribing decisions focused more directly on removing offending medications, versus exploring hypothesized physiologic factors such as HDL-C, because earlier recognition of drug-induced movement disorders permits rapid intervention and decreased risk of permanently disfiguring and debilitating extrapyramidal symptoms,” the authors write.<\/p>\n